We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule in... Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California. Show more
Ask ADVFN Intelligence (AI)
- Phase 1b trial will evaluate receptor occupancy of PIPE-791 in the brain and lungs of patients in multiple cohorts using a PET tracer of the LPA1 receptor - Topline data readout planned for the...
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that...
- Phase 1b study for the potential treatment of osteoarthritis and low back pain expected to commence in the first quarter of 2025 - Initial data readout planned for early 2026 - Neuropathic...
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that...
-Enrollment for PIPE-307 VISTA trial on track- -Strong cash position of $214 million at the end of Q3 expected to support operations through 2027- -Multiple potential clinical readouts in...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.01 | 7.53731343284 | 13.4 | 14.41 | 12.64 | 283941 | 13.60905129 | CS |
| 4 | -0.94 | -6.12377850163 | 15.35 | 15.4 | 12.64 | 131305 | 13.85824915 | CS |
| 12 | -4.67 | -24.4758909853 | 19.08 | 20.24 | 12.33 | 104191 | 15.59177289 | CS |
| 26 | -3.98 | -21.6421968461 | 18.39 | 22 | 12.33 | 87188 | 17.247308 | CS |
| 52 | -0.09 | -0.620689655172 | 14.5 | 22 | 12.33 | 87310 | 16.93597665 | CS |
| 156 | -0.09 | -0.620689655172 | 14.5 | 22 | 12.33 | 87310 | 16.93597665 | CS |
| 260 | -0.09 | -0.620689655172 | 14.5 | 22 | 12.33 | 87310 | 16.93597665 | CS |
Monksdream
3 months ago
UpTickMeA$AP
8 months ago
UpTickMeA$AP
9 months ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
